ArticleOrphanet journal of rare diseases2026
Global burden of Wilson disease: a comprehensive evidence synthesis.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWilson disease (WD) is a rare inherited copper metabolism disorder with variable prevalence worldwide. Many regions lack reliable data, leading to underestimation of burden. WD presents with hepatic, neurological, and psychiatric symptoms, but mental health impacts and economic costs are often overlooked.
methodsWe systematically searched PubMed up to July 2025 for studies reporting WD prevalence, clinical features, quality of life, or economic burden. Disability-adjusted life years (DALYs) were estimated, and temporal trends were analyzed. Meta-analyses pooled epidemiological and clinical data. Forecast models predicted future prevalence and costs.
resultsA total of 136 studies were included. Prevalence varied, being higher in Southern Europe and parts of Asia, but lower in Northern/Eastern Europe. Rising prevalence was observed in Morocco, South Korea, Spain, and Germany, likely due to improved recognition. Forecasts suggest a gradual global increase through 2030. WD mainly affects young individuals (mean age 19.9 years), with hepatic involvement in 72% and acute liver failure in 31%. Overall mortality was 14%. Mental health complications were frequent, with depression in 47.7% and anxiety in 40%. DALYs have risen globally since the 1970s, with China, the U.S., and Poland projected to carry the heaviest future burden. Economic costs are substantial, particularly in the U.S., where annual hospitalization per patient may exceed USD 60,000.
conclusionWD imposes significant clinical, psychological, and economic burdens worldwide. Improved early diagnosis, standardized treatment, and comprehensive care are needed to reduce morbidity, enhance quality of life, and lower healthcare costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.